TREATMENT OF IDIOPATHIC ASTHENOZOOSPERMIE WITH COENZYME Q10. A DOUBLE BLIND CONTROLLED STUDY - ND

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-006105-40-IT

Enrollment

Registered

2006-08-30

Start date

2006-06-05

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IDIOPATHIC ASTHENOZOOSPERMIA MedDRA version: 6.1 Level: HLT Classification code 10013358

Interventions

Trade Name: MYOQUINON Pharmaceutical Form: Capsule, soft Current Sponsor code: COQ10 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of th

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: MALES PATIENTS WITH AN INFERTILITY HISTORY OF AT LEAST 2 YEARS, AFFECTED BY IDIOPATHIC ASTHENOZOOSPERMIE ACCORDING WHO 1999 CRITERIA AND NORMAL LEVELS OF GONODOTROPINS Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: HYPOGONADOTROPIC HIPOGONADISM, SEMINAL TRACT OBSTRUCTION, VARICOCELE, INFLAMMATORY AND INFECTIONS OF GENITAL TRACTS POSITIVE REACTION AFTER MAR-TEST, OTHER CHRONIC PATOLOGIES DRUGS THERAPIES

Design outcomes

Primary

Measure	Time frame
Main Objective: TO EVALUATE THE EFFECTS OF COENZYME Q10 ADMINISTRATION ON SEMEN PARAMETERS;Secondary Objective: TO EVALUATE THE EFFECTS OF COENZYME Q10 AMMINISTRATION ON PREGNANCY RATE;Primary end point(s): SPERM MOTILITY VARIATIONS INCLUDING COMPUTER-SISTED ANALYSIS AND COENZYME Q10 VARIATIONS IN SEMINAL PLASMA AND SPERM CELLS AFTER SIX MONTHS OF THERAPY	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026